Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery. - Full Text View

Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery. (REMISYD)

This study is currently recruiting participants.

Verified by Kuopio University Hospital, April 2009

First Received: September 22, 2008 Last Updated: April 21, 2009 History of Changes

Sponsored by:	Kuopio University Hospital
Information provided by:	Kuopio University Hospital
ClinicalTrials.gov Identifier:	NCT00757198

Purpose

Prospective double blind study comparing two remifentanil dosing protocols (0.1 and 0.3 mcg/kg/min) during cardiac surgery. Main outcome measures are postoperative opioid requirements (PCA oxycodone) and postoperative pain (VAS, verbal rating scale).

Condition	Intervention	Phase
Pain	Drug: remifentanil	Phase IV

MedlinePlus related topics: Heart Surgery Surgery

Drug Information available for: Remifentanil hydrochloride Remifentanil

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study
Official Title:	Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.

Further study details as provided by Kuopio University Hospital:

Primary Outcome Measures:

Postoperative opioid (oxycodone) consumption [ Time Frame: Postoperatively 48 hours ] [ Designated as safety issue: No ]

Estimated Enrollment:	90
Study Start Date:	September 2008
Estimated Study Completion Date:	March 2011
Estimated Primary Completion Date:	November 2010 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental remifentanil o.1 mcg/kg/min	Drug: remifentanil remifentanil infusion
2: Active Comparator remifentanil 0.3 mcg/kg/min	Drug: remifentanil remifentanil infusion

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Coronary artery bypass grafting patients

Exclusion Criteria:

Psychiatric disorders, sleep apnea, cardiac insufficiency

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00757198

Contacts

Contact: Pasi Lahtinen, MD	+358-40-7368286	pasi.lahtinen@kuh.fi
Contact: Pawel Florkiewicz, MD	+358-40-3539440	pawel.florkiewicz@kuh.fi

Locations

Finland
Kuopio University hospital	Recruiting
Kuopio, Finland, 70210
Contact: Pasi Lahtinen pasi.lahtinen@kuh.fi
Sub-Investigator: Tadeusz Musialowicz, MD

Sponsors and Collaborators

Kuopio University Hospital

Investigators

Study Director:

Pasi Lahtinen, MD

Department of Anesthesiology and Intensive Care, Kuopio University hospital, Kuopio, Finland

More Information

No publications provided

Responsible Party:	Kuopio university hospital/Department of Anesthesiology and intensive care ( Pasi Lahtinen )
Study ID Numbers:	KUH5070206, EudraCT 2008-000597-21
Study First Received:	September 22, 2008
Last Updated:	April 21, 2009
ClinicalTrials.gov Identifier:	NCT00757198 History of Changes
Health Authority:	Finland: National Agency for Medicines

Keywords provided by Kuopio University Hospital:

pain, postoperative, opioid, PCA, cardiac surgery

Study placed in the following topic categories:

Anesthetics, Intravenous
Remifentanil
Anesthetics, General
Hypnotics and Sedatives
Anesthetics
Central Nervous System Depressants

Pain
Peripheral Nervous System Agents
Analgesics
Analgesics, Opioid
Pain, Postoperative

Additional relevant MeSH terms:

Anesthetics, Intravenous
Remifentanil
Physiological Effects of Drugs
Anesthetics
Central Nervous System Depressants
Pharmacologic Actions
Sensory System Agents

Anesthetics, General
Therapeutic Uses
Hypnotics and Sedatives
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on May 07, 2009